Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Jordan Healthcare Press.
Press releases published on August 14, 2025
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 14, 2025
—Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug’s Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects …
Lifeward Ltd. Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic …
PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)
GlobeNewswire
·
August 14, 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today that Fabio …
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
GlobeNewswire
·
August 14, 2025
Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney damage and disease progression. Earlier data by Kanbay et al (Eur J Clin Invest. 2022) demonstrate …
Healthcare Innovation Summit Africa Returns to Johannesburg - Registration Now Open
GlobeNewswire
·
August 14, 2025
JOHANNESBURG, South Africa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Healthcare Innovation Summit Africa (HISA) 2025, Africa’s leading platform for exploring the latest trends and technologies shaping the healthcare industry, will return to Johannesburg on 22 …
OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth
GlobeNewswire
·
August 14, 2025
MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced its financial results for the second quarter ended June 30, 2025, …
Avicanna Reports Q2 2025
GlobeNewswire
·
August 14, 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Evaxion announces business update and second quarter 2025 financial results
GlobeNewswire
·
August 14, 2025
COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2025 financial results. …
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
GlobeNewswire
·
August 14, 2025
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide® may catalyze LM treatment initiation, allow physicians to adapt treatment with real time shifts in tumor biology, …
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 14, 2025
Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026 Top-line …
Cassava Reports Q2 2025 Financials Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy Recent appointment of experienced neuroscience leaders to guide the clinical …
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
August 14, 2025
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch on …
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy On track …
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
GlobeNewswire
·
August 14, 2025
Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical …
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
August 14, 2025
Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and …
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
GlobeNewswire
·
August 14, 2025
Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric Cancer Department of Defense STTR Grant to advance INKTs in GVHD announced; program advancing New clinical grant awarded to launch AgenT-797 in GvHD clinical trial; …
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
GlobeNewswire
·
August 14, 2025
Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for International Medical Cannabis International Medical sales now 57% of Total Revenue Cash Balance of $10.4 Million at the end of Q2, Increased from $8.4 Million in Q1 …
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
August 14, 2025
Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway Continue to Work …
CRB Expands Life Sciences Leadership Team with Appointment of Senior Director Eric Hanson
GlobeNewswire
·
August 14, 2025
Kansas City, Mo., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CRB, a leading provider of sustainable engineering, architecture, construction, and consulting services for the life sciences and food and beverage industries, today announced the appointment of Eric …
EvolveImmune Therapeutics Announces FDA Clearance of Investigational New Drug Application for EVOLVE104, a Novel Trispecific T Cell Engager with Integrated CD2 Costimulation
GlobeNewswire
·
August 14, 2025
First Program from EVOLVE T-Cell Engager Platform to Advance into Clinical Development Phase 1 Clinical Trial of EVOLVE104 to be Initiated in 2025 BRANFORD, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company …